Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Allogeneic Stem Cell Transplantation In Adults With High Risk Acute Lymphoblastic Leukemia (ALL) In 1. Remission (CR1): Promising, But Strongly Influenced By ALL Subtypes

Renate Arnold, MD, Theis H. Terwey, MD, Giang Lam Vuong, MD, Benjamin Ostendorf, MD, Olaf Penack, MD, Gero Massenkeil, MD, Nicola Gökbuget, MD, Philipp Hemmati, MD

Blood (2013) 122 (21): 3409.

https://doi.org/10.1182/blood.V122.21.3409.3409

Published: 2013

Journal Articles

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Jan Braess, MD, Karl-Anton Kreuzer, Karsten Spiekermann, PhD, Hans Walter Lindemann, MD, Eva Lengfelder, MD, Ullrich Graeven, Peter Staib, MD, Wolf-Dieter Ludwig, Harald Biersack, Yon-Dschun Ko, MD, Michael J. Uppenkamp, Stefan Korsten, Maike De Wit, Rudolf Peceny, MD, Tobias Gaska, MD, Xaver Schiel, Dirk M Behringer, MD, Michael G. Kiehl, MD, PhD, Bettina Zinngrebe, Gerald Meckenstock, Eva Roemer, Dirk Medgenberg, Ernst Spaeth-Schwalbe, MD, Birgit Braess, MD, Gero Massenkeil, MD, Heidrun Hindahl, Guido Trenn, Rainer Schwerdtfeger, MD, Susanne Amler, MSc, Cristina Sauerland, MSc, Andreas Faldum, MD, Michael Unterhalt, M.D. Ph.D., Stefan K. Bohlander, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Christian Buske, MD, Michael Fiegl, MD, Marion Subklewe, MD, Anja Baumgartner, PhD, Bernhard J. Woermann, MD, Dietrich Beelen, MD, Wolfgang Hiddemann, MD

Blood (2013) 122 (21): 619.

https://doi.org/10.1182/blood.V122.21.619.619

Published: 2013

Journal Articles

Impact of Early Blast Clearance Following Induction Chemotherapy On the Outcome of Patients with Acute Myelod Leukemia Undergoing Allogeneic Stem Cell Transplantation in First Complete Remission

Philipp G. Hemmati, MD, Theis H. Terwey, MD, Philipp le Coutre, MD, Gero Massenkeil, MD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2012) 120 (21): 1998.

https://doi.org/10.1182/blood.V120.21.1998.1998

Published: 2012

Journal Articles

Prognostic Impact of a Monosomal Karyotype on the Outcome of Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation

Philipp G. Hemmati, Theis H. Terwey, Philipp D. le Coutre, MD, Christian Ziegler, Grzegorz Kofla, Gero Massenkeil, MD, Bernd Dörken, Renate Arnold

Blood (2011) 118 (21): 2028.

https://doi.org/10.1182/blood.V118.21.2028.2028

Published: 2011

Journal Articles

Allogeneic Stem Cell Transplantation for Secondary or Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome with Poor-Risk Cytogenetics.

Philipp G. Hemmati, MD, Theis Terwey, MD, Philipp D. le Coutre, MD, Gero Massenkeil, MD, Lam G Vuong, MD, PhD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2010) 116 (21): 3470.

https://doi.org/10.1182/blood.V116.21.3470.3470

Published: 2010

Journal Articles

Pre-Transplant Risk-Assessment for Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplants.

Philipp G. Hemmati, MD, Theis H. Terwey, MD, Philipp le Coutre, MD, Gero Massenkeil, MD, Lam G Vuong, PhD, Christian Jakob, MD, Arturo Vega, MD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2009) 114 (22): 2302.

https://doi.org/10.1182/blood.V114.22.2302.2302

Published: 2009

Journal Articles

Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Combined with Leukemic Risk Factors Predict Outcome of AML Patients after Allogeneic Stem Cell Transplantation Following Reduced Intensity Conditioning (RIC).

Philipp Hemmati, Theis Terwey, Gero Massenkeil, MD, Philipp D. le Coutre, MD, Stefan Neuburger, Lam G Vuong, Bernd Dörken, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 3276.

https://doi.org/10.1182/blood.V112.11.3276.3276

Published: 2008

Journal Articles

Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation in AML Patients with An Intermediate Risk Karyotype: No Difference in Outcome as Compared to Standard Myeloablative Conditioning (MAC).

Philipp Hemmati, Gero Massenkeil, MD, Theis Terwey, Stefan Neuburger, Philipp D. le Coutre, MD, Lam G Vuong, Bernd Dörken, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 3278.

https://doi.org/10.1182/blood.V112.11.3278.3278

Published: 2008

Journal Articles

Secondary Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Stefan Neuburger, MD, Philipp Hemmati, MD, Theis Terwey, MD, Gero Massenkeil, MD, Bernd Dörken, MD, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 4297.

https://doi.org/10.1182/blood.V112.11.4297.4297

Published: 2008

Journal Articles

Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning (RIC) Is Effective for Long-Term Disease Control in High-Risk AML Patients in First Complete Remission.

Philipp G. Hemmati, MD, Gero Massenkeil, MD, Theis H. Terwey, MD, Stefan Neuburger, MD, Philipp le Coutre, MD, Lam Vuong, MD, Bernd Dorken, MD, Renate Arnold, MD

Blood (2007) 110 (11): 3020.

https://doi.org/10.1182/blood.V110.11.3020.3020

Published: 2007

Journal Articles

Treatment Strategies for Patients with Relapsed Acute Lymphoblastic Leukemia: Allogeneic Stem Cell Transplantation Is Effective without Prior Reinduction Chemotherapy.

Theis H. Terwey, MD, Gero Massenkeil, MD, Ingo Tamm, MD, Christoph Lutz, MD, Philipp Hemmati, MD, Stefan Neuburger, MD, Bernd Dorken, MD, Renate Arnold, MD

Blood (2006) 108 (11): 3004.

https://doi.org/10.1182/blood.V108.11.3004.3004

Published: 2006

Journal Articles

Severe Alterations of Bone Mass and Bone Structure after Allogeneic Stem Cell Transplantation: An Osteopathologic Analysis.

Gero Massenkeil, MD, Cornelia Fiene, MD, Oliver Rosen, MD, Bernd Doerken, MD, Renate Arnold, MD, Guenther Delling, MD

Blood (2006) 108 (11): 3025.

https://doi.org/10.1182/blood.V108.11.3025.3025

Published: 2006

Journal Articles

Structural and Complex Chromosomal Aberrations Frequently Develop in Skin Fibroblasts after Allogeneic Stem Cell Transplantation.

Gero Massenkeil, MD, Petra Zschieschang, MD, Julia Pross, Ingo Tamm, MD, Stephan Neuburger, MD, Christoph Lutz, MD, Oliver Rosen, MD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2005) 106 (11): 1118.

https://doi.org/10.1182/blood.V106.11.1118.1118

Published: 2005

Journal Articles

Reduced Intensity Conditioning in Acute Leukemias: Long Term Follow-Up Confirms Sustained Complete Remissions.

Gero Massenkeil, MD, Stefan Neuburger, MD, Ingo Tamm, MD, Christoph Lutz, MD, Marion Nagy, PhD, Philipp Le Coutre, MD, Bernd Doerken, MD, Renate Arnold, MD

Blood (2004) 104 (11): 5147.

https://doi.org/10.1182/blood.V104.11.5147.5147

Published: 2004

Journal Articles

Donor Lymphocyte Infusions to Prevent Relapse in Acute Leukemias after Allogenic Stem Cell Transplantation.

Christoph Lutz, MD, Marion Nagy, PhD, Ingo Tamm, MD, Stefan Neuburger, MD, Bernd Doerken, MD, Renate Arnold, MD, Gero Massenkeil, MD

Blood (2004) 104 (11): 1642.

https://doi.org/10.1182/blood.V104.11.1642.1642

Published: 2004

NARROW

Allogeneic Stem Cell Transplantation In Adults With High Risk Acute Lymphoblastic Leukemia (ALL) In 1. Remission (CR1): Promising, But Strongly Influenced By ALL Subtypes

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Impact of Early Blast Clearance Following Induction Chemotherapy On the Outcome of Patients with Acute Myelod Leukemia Undergoing Allogeneic Stem Cell Transplantation in First Complete Remission

Prognostic Impact of a Monosomal Karyotype on the Outcome of Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation for Secondary or Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome with Poor-Risk Cytogenetics.

Pre-Transplant Risk-Assessment for Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplants.

Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Combined with Leukemic Risk Factors Predict Outcome of AML Patients after Allogeneic Stem Cell Transplantation Following Reduced Intensity Conditioning (RIC).

Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation in AML Patients with An Intermediate Risk Karyotype: No Difference in Outcome as Compared to Standard Myeloablative Conditioning (MAC).

Secondary Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning (RIC) Is Effective for Long-Term Disease Control in High-Risk AML Patients in First Complete Remission.

Treatment Strategies for Patients with Relapsed Acute Lymphoblastic Leukemia: Allogeneic Stem Cell Transplantation Is Effective without Prior Reinduction Chemotherapy.

Severe Alterations of Bone Mass and Bone Structure after Allogeneic Stem Cell Transplantation: An Osteopathologic Analysis.

Structural and Complex Chromosomal Aberrations Frequently Develop in Skin Fibroblasts after Allogeneic Stem Cell Transplantation.

Reduced Intensity Conditioning in Acute Leukemias: Long Term Follow-Up Confirms Sustained Complete Remissions.

Donor Lymphocyte Infusions to Prevent Relapse in Acute Leukemias after Allogenic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only